Alethio Therapeutics was founded to develop medicines that alter disease progression in myeloproliferative neoplasms (MPNs), based on research at the University of Oxford and clinical experience.
Alethio Therapeutics develops disease-modifying therapies for myeloproliferative neoplasms (MPNs), building on research from the University of Oxford and expertise from two haematologist physician-scientists.
Alethio Therapeutics is harnessing deep expertise to develop disease-modifying therapies that that could transform outcomes for patients with chronic blood cancers.
Alethio Therapeutics secures $90 million in Series A funding to develop treatments for myeloproliferative neoplasms (MPNs), a group of rare blood cancers. Investors highlight the potential for its drug to address a broader range of conditions than existing approved therapies. The company focuses on novel approaches to improve patient outcomes in these underserved diseases.
